Clinical Trial

Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

Study acronym: (COBRA)
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2018-10-31; most recent amendment 2026-03-02.
Status change: Recruiting → Active, Not Recruiting 2024-08-14
Status change: Not Yet Recruiting → Recruiting 2019-05-24
Trial Details
NCT Number NCT03729804
Lead Sponsor University of Chicago
Conditions Multiple Myeloma
Enrollment 250 participants
Start Date 2019-05-07
Primary Completion 2026-12-28 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-04